文献速递前列腺癌

前列腺癌大分割调强放疗中使用直肠内气囊与直肠出血风险

Risk of rectal bleeding with endorectal balloon use after hypofractionated intensity-modulated radiotherapy for prostate cancer.
PubMed 文献 · BJU Int · 2026-02-13

本研究纳入2018至2020年230例接受根治性中度大分割调强放疗的前列腺癌患者,比较使用与不使用直肠内气囊(ERB)对直肠出血及内镜改变的影响。结果显示ERB组5年≥2级直肠出血累积发生率为27.7%,非ERB组为9.0%(P<0.001),ERB使用与出血风险独立相关(HR 3.45;95%CI 1.68-7.07;P<0.001),而肿瘤学结局两组相当。

要点

  • ERB组5年≥2级直肠出血累积发生率为27.7%,显著高于非ERB组的9.0%。
  • ERB使用与直肠出血风险独立相关,调整及匹配队列结果一致。
  • ERB组毛细血管扩张、黏膜充血及VRS≥3比例更高,尤其放疗后前3年。

核心结论

  • 中度大分割调强放疗中使用ERB与直肠出血显著增加相关,而肿瘤学结局无显著差异。
  • 在缺乏患者获益证据的情况下,不支持在前列腺癌放疗中常规使用ERB。

研究设计与样本

  • 2018至2020年纳入230例接受根治性中度大分割调强放疗的前列腺癌患者,分为使用与不使用ERB两组。
  • 根据胃肠道症状或临床判断进行内镜评估,直肠毒性按CTCAE分级,内镜表现采用Vienna直肠镜评分(VRS)。

主要发现

  • 5年≥2级直肠出血累积发生率非ERB组为9.0%,ERB组为27.7%(P<0.001)。
  • 多变量分析中ERB使用与直肠出血风险增加独立相关(HR 3.45;95%CI 1.68-7.07;P<0.001),调整及匹配队列结果一致。
  • ERB组毛细血管扩张、黏膜充血及VRS≥3比例显著更高,尤其放疗后前3年。
  • VRS随时间呈二次轨迹变化,约2-3年达峰后下降。
  • 生化失败、远处进展及总生存等肿瘤学结局两组相当。

关键数值与推荐

  • 5年≥2级直肠出血累积发生率:非ERB组9.0%,ERB组27.7%(P<0.001)。
  • ERB使用与直肠出血风险的多变量HR为3.45(95%CI 1.68-7.07;P<0.001)。

临床怎么用

  • 在前列腺癌中度大分割调强放疗中,不应常规使用ERB。
  • 对使用ERB的患者应加强直肠出血监测与内镜随访,尤其放疗后前3年。

局限性

  • 内镜评估基于症状或临床判断,非全部患者系统性进行。
  • 为单中心回顾性设计,ERB使用非随机分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the long-term impact of endorectal balloon (ERB) use on rectal bleeding and endoscopic changes among patients who underwent symptom-driven endoscopic evaluation after moderately hypofractionated intensity-modulated radiotherapy (IMRT) for prostate cancer. PATIENTS AND METHODS: Between 2018 and 2020, 230 patients with prostate cancer underwent definitive moderately hypofractionated IMRT with or without ERB. Endoscopic assessment was performed based on gastrointestinal symptoms or clinical judgement. Rectal toxicity was assessed clinically and graded according to the Common Terminology Criteria for Adverse Events, while endoscopic findings were scored using the Vienna Rectoscopy Score (VRS). RESULTS: The 5-year cumulative incidence of Grade ≥2 rectal bleeding was 9.0% in the non-ERB group and 27.7% in the ERB group (P < 0.001). In multivariable analysis, ERB use was independently associated with an increased risk of rectal bleeding (hazard ratio 3.45; 95% confidence interval 1.68-7.07; P < 0.001), and this association was consistent across adjusted and matched cohorts. Endoscopic evaluation showed significantly higher rates of telangiectasia, mucosal congestion, and VRS ≥3 in the ERB group, particularly during the first 3 years after radiotherapy. Temporal changes in VRS followed a quadratic trajectory, peaking at approximately 2-3 years and subsequently declining. Oncological outcomes, including biochemical failure, distant progression, and overall survival, were comparable between the groups. CONCLUSIONS: Endorectal balloon use during moderately hypofractionated IMRT was associated with significantly greater rectal bleeding, while oncological outcomes did not differ significantly. In the absence of demonstrated patient benefit, our findings do not support the routine use of ERB in contemporary prostate radiotherapy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Jang JY, Lee JH, Pyo H, et al. Risk of rectal bleeding with endorectal balloon use after hypofractionated intensity-modulated radiotherapy for prostate cancer. BJU Int. 2026. PMID: 41685719. doi:10.1111/bju.70175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。